← All indications
Hypertrophy, Left Ventricular
Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
Subtype terms (1)
More specific conditions that are subtypes of Hypertrophy, Left Ventricular in the MeSH hierarchy.
Drugs by status
Phase 4 trials (49)
- ferric derisomaltose
- allopurinol
- alfacalcidol
- vitamin e
- astaxanthin
- dabigatran
- candesartan
- chlorthalidone
- tadalafil
- alpha-lipoic acid
- diltiazem
- empagliflozin
- tacrolimus
- l-glutamine
- amlodipine
- calcium
- potassium
- warfarin
- icosapent ethyl
- levosimendan
- pegvisomant
- ticagrelor
- valsartan
- propranolol
- alirocumab
- sitagliptin
- acetylsalicylic acid
- mycophenolate
- aliskiren
- sucrosomial iron
- +19 more
Phase 3 trials (23)
Phase 2 trials (21)
- omecamtiv mecarbil
- nitroglycerin
- alagebrium
- atrial natriuretic peptide
- azd-1305
- mirabegron
- echitabplus-icp
- iloprost
- nitrogen
- nitric oxide
- trastuzumab
- pertuzumab
- fluorescein
- trastuzumab emtansine
- allogeneic adipose derived mesenchymal stem cell
- autologous human c-kit cscs ii
- cardiac stem cells
- autologous mesenchymal stem cells
- fludeoxyglucose f-18
- mavacamten
- Nitroxyl donor
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (25)
- Bristol-Myers Squibb
- AstraZeneca
- Pfizer
- Sanofi
- Novartis
- Allergan
- Boehringer Ingelheim
- Aarhus University
- Instituto de Urologia e Nefrologia
- Julius-Maximilians University
- Nagoya University
- Mustafa Kemal University
- Trinity Hypertension & Metabolic Research Institute
- University of Dundee
- University of Glasgow
- University of Toronto
- Poznan University
- University of Ulsan
- University of Vienna
- Hanmi Pharmaceutical
- British Heart Foundation
- University of Barcelona
- Applied Health Research Centre
- The University of Texas, Dallas
- Canadian Medical and Surgical Knowledge Translation Research Group
Organization Involved with Phase 3 Indications (17)
- Abbott
- AbbVie
- Merck
- GlaxoSmithKline
- Fundación Lindavista del Corazón AC
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Harvard University
- Indiana University
- University of Southern Denmark
- University of Sussex
- University of Birmingham
- University of Limoges
- Cha Medical University
- Mario Negri Institute
- Janssen Pharmaceutica NV
- Agenzia Italiana del Farmaco
- Johnson and Johnson
Organization Involved with Phase 2 Indications (14)
- Synvista Therapeutics, Inc
- University of Pennsylvania
- University of Lisbon
- University of Athens
- Wroclaw Medical University
- Université catholique de Louvain
- University of Oxford
- European Society of Cardiology
- University of Nantes
- University of Goettingen
- University of Brescia
- Department of Veteran Affairs
- European Commission
- European Clinical Research Infrastructure Network
Organization Involved with Other Experimental Indications (7)